Cancer Suicide Gene Therapy with TK.007
Cancer is a devastating disease characterized by uncontrolled and aggressive cell growth. Suicide gene therapy (SGT) facilitating induction of malignancy-specific cell death represents a novel therapeutic approach to treat cancer, which has been investigated in several cancer types with very promising results. In addition, SGT has been suggested as a safeguard in adoptive immunotherapy and regenerative-medicine settings. Generally, SGT consists of two steps—vector-mediated delivery of suicide genes into tumors and subsequent activation of the suicide mechanism, e.g., by administration of a specific prodrug. This chapter provides a framework of protocols for basic and translational research using the Herpes-simplex-virus thymidine kinase (HSV-TK)/ganciclovir (GCV) system, the most widely used suicide gene approach. The protocols provide standard guidelines for the preparation of high-titer third-generation lentiviral vectors encoding a genetically improved HSV-TK version known as TK.007 and its application in in vitro and in vivo treatment setups.
Key wordsCancer gene therapy Suicide gene therapy HSV-TK Lentiviral vectors Glioblastoma
- 9.Springer CJ, Niculescu-Duvaz I (2005) Suicide gene therapy. In: Curiel DT, Douglas JT (eds) Cancer gene therapy: contemporary cancer research. Humana Press, Clifton, NJGoogle Scholar
- 17.Fehse B, Ayuk FA, Kroger N et al (2004) Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells. Blood 104:3408–3409. https://doi.org/10.1182/blood-2004-07-2813 CrossRefPubMedGoogle Scholar
- 18.Balzarini J, Liekens S, Solaroli N et al (2006) Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation. J Biol Chem 281:19273–19279. https://doi.org/10.1074/jbc.M600414200 CrossRefPubMedGoogle Scholar